Loading company…
Precirix NV, based in Brussels, develops precision radiopharmaceuticals for cancer, with a lead candidate targeting FAP.
Founded in 2014 and headquartered in Brussels, Belgium, Precirix NV develops precision radiopharmaceuticals for cancer. Its lead candidate targets Fibroblast Activation Protein (FAP) using camelid single-domain antibodies labeled with radiometals, and is moving into clinical trials. The company raised EUR 80.000 mn in its Series A funding round on March 16, 2022, led by investors including BioMed Partners and Forbion. Ruth Devenyns is CEO, and Geert Raes, Jens De Vos and Matthias D'Huyvetter are founders.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in